About this trial
Pulmonary vein isolation is an established intervention for atrial fibrillation. Patients with a paroxysmal atrial fibrillation have no or only few comorbidities and a good prognosis in respect to their atrial fibrillation. In contrast, patients with persistent atrial fibrillation often suffer from relevant comorbidities and recurrence of atrial fibrillation is common. Left-atrial fibrosis and its electrophysiological consequences are involved in the recurrence rate, but pathophysiological mechanisms are yet to be better characterized. The study investigates relevant comorbidities to elucidated their effect on atrial fibrosis and recurrence rates of atrial fibrillation. Furthermore, the investigators evaluate the prevalence of these comorbidities.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
persistent atrial fibrillation, eligible for ablation
BMI 19-40
Disqualifiers
valvular atrial fibrillation
formerly ablation
medication interfereing with measurements of atrial fibrosis
known or treated comorbidities (OSAS, PA)
Trial population
Patients with persistent atrial fibrillation, eligible for ablation
Trial design
Case-only
Prospective
Treatments tested in this trial
Screening on comorbidites
Diagnostic testPatients with persistent atrial fibrillation that undergo ablation are screened for comorbidities
Treatment groups
Trial outcomes
Primary outcomes
quantification of area of left-atrial fibrosis in the heart
During ablation elecrical maping of the left-atrium is done and percentage of left-atrial fibrosis (electrical tissue abnormalities) will be assessed
Rate of recurrence of atrial fibrillation (yes/no) in the study group
measure the recurrence of AF in follow-up with holter-ekgs
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Christina Berr. MD
Lead sponsor
University Hospital Augsburg
Sponsor institution